RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, PCVX, LEGN, JANX, AVTE, and represent 38.97% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: EWTX (+$163M), DYN (+$141M), EVH (+$105M), Lenz Therapeutics (+$93M), LBPH (+$71M), DNTH (+$70M), ATXS (+$62M), Cg Oncology (+$61M), TYRA (+$52M), PRAX (+$51M).
- Started 21 new stock positions in RGLS, IMTX, EWTX, LRMR, DNTH, DYN, Lenz Therapeutics, PRAX, Cg Oncology, LBPH. CRVO, EYPT, ATXS, Boundless Bio, LXEO, SERA, Alto Neuroscience, ACET, Metagenomi, CYBN, VXRT.
- Reduced shares in these 10 stocks: , Cymabay Therapeutics (-$164M), Icosavax (-$94M), ALPN (-$94M), INBX (-$73M), MGNX (-$29M), TSHA (-$22M), Harpoon Therapeutics (-$17M), CMPS, CNTB.
- Sold out of its positions in ALPN, CNTB, Cymabay Therapeutics, Harpoon Therapeutics, Icosavax, ImmunoGen, SABS.
- Ra Capital Management was a net buyer of stock by $280M.
- Ra Capital Management has $7.9B in assets under management (AUM), dropping by 22.77%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 76 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/s - SH (ASND) | 19.4 | $1.5B | 10M | 151.17 |
|
|
| Vaxcyte SH (PCVX) | 7.1 | $560M | +3% | 8.2M | 68.31 |
|
| Legend Biotech Corp- SH (LEGN) | 4.9 | $385M | +9% | 6.9M | 56.09 |
|
| Janux Therapeutics SH (JANX) | 4.4 | $345M | 9.2M | 37.65 |
|
|
| Aerovate Therapeutics SH (AVTE) | 3.1 | $244M | 8.3M | 29.57 |
|
|
| Rhythm Pharmaceuticals SH (RYTM) | 2.9 | $231M | 5.3M | 43.33 |
|
|
| Evolent Health Inc - A SH (EVH) | 2.4 | $188M | +125% | 5.7M | 32.79 |
|
| Newamsterdam Pharma Co Nv SH (NAMS) | 2.4 | $186M | 7.9M | 23.65 |
|
|
| Rxsight SH (RXST) | 2.3 | $178M | 3.4M | 51.58 |
|
|
| Tyra Biosciences SH (TYRA) | 2.2 | $171M | +43% | 10M | 16.40 |
|
| Edgewise Therapeutics SH (EWTX) | 2.1 | $163M | NEW | 8.9M | 18.24 |
|
| 4d Molecular Therapeutics In SH (FDMT) | 2.0 | $161M | +21% | 5.1M | 31.86 |
|
| Biogen SH (BIIB) | 2.0 | $160M | +39% | 741k | 215.63 |
|
| Pepgen SH (PEPG) | 2.0 | $157M | +31% | 11M | 14.70 |
|
| Geron Corp SH (GERN) | 1.9 | $153M | 46M | 3.30 |
|
|
| 89bio SH (ETNB) | 1.9 | $149M | +11% | 13M | 11.64 |
|
| Dyne Therapeutics SH (DYN) | 1.8 | $141M | NEW | 5.0M | 28.39 |
|
| Apogee Therapeutics SH (APGE) | 1.7 | $131M | 2.0M | 66.45 |
|
|
| Day One Biopharmaceuticals I SH (DAWN) | 1.6 | $129M | 7.8M | 16.52 |
|
|
| Nkarta SH (NKTX) | 1.5 | $117M | +38% | 11M | 10.81 |
|
| Wave Life Sciences SH (WVE) | 1.4 | $112M | 18M | 6.17 |
|
|
| Ars Pharmaceuticals SH (SPRY) | 1.4 | $111M | +14% | 11M | 10.22 |
|
| Fulcrum Therapeutics SH (FULC) | 1.4 | $110M | 12M | 9.44 |
|
|
| Verona Pharma Plc - SH (VRNA) | 1.3 | $102M | 6.3M | 16.09 |
|
|
| Lenz Therapeutics SH | 1.2 | $93M | NEW | 4.2M | 22.33 |
|
| Inhibrx SH (INBX) | 1.2 | $92M | -44% | 2.6M | 34.96 |
|
| Avidity Biosciences SH (RNA) | 1.1 | $84M | +33% | 3.3M | 25.52 |
|
| Axsome Therapeutics SH (AXSM) | 1.0 | $80M | 1.0M | 79.80 |
|
|
| Longboard Pharmaceuticals In SH (LBPH) | 0.9 | $71M | NEW | 3.3M | 21.60 |
|
| Dianthus Therapeutics SH (DNTH) | 0.9 | $70M | NEW | 2.3M | 30.00 |
|
| Gh Research SH (GHRS) | 0.8 | $67M | +11% | 6.3M | 10.66 |
|
| Structure Therapeutics SH (GPCR) | 0.8 | $65M | +210% | 1.5M | 42.86 |
|
| Mineralys Therapeutics SH (MLYS) | 0.8 | $63M | +52% | 4.9M | 12.91 |
|
| Astria Therapeutics SH (ATXS) | 0.8 | $62M | NEW | 4.4M | 14.07 |
|
| Cg Oncology SH | 0.8 | $61M | NEW | 1.4M | 43.90 |
|
| Acumen Pharmaceuticals SH (ABOS) | 0.8 | $61M | 15M | 4.05 |
|
|
| Iteos Therapeutics SH (ITOS) | 0.8 | $60M | 4.4M | 13.64 |
|
|
| Solid Biosciences SH (SLDB) | 0.7 | $58M | +26% | 4.3M | 13.32 |
|
| Madrigal Pharmaceuticals SH (MDGL) | 0.7 | $55M | 205k | 267.04 |
|
|
| Vor Biopharma SH (VOR) | 0.7 | $54M | 23M | 2.37 |
|
|
| Praxis Precision Medicines I SH (PRAX) | 0.6 | $51M | NEW | 828k | 61.02 |
|
| Urogen Pharma SH (URGN) | 0.6 | $46M | 3.1M | 15.00 |
|
|
| Larimar Therapeutics SH (LRMR) | 0.6 | $46M | NEW | 6.0M | 7.59 |
|
| Cytek Biosciences SH (CTKB) | 0.6 | $46M | 6.8M | 6.71 |
|
|
| C4 Therapeutics SH (CCCC) | 0.5 | $40M | 4.9M | 8.17 |
|
|
| Werewolf Therapeutics SH (HOWL) | 0.5 | $40M | 6.1M | 6.48 |
|
|
| Enliven Therapeutics SH (ELVN) | 0.5 | $37M | 2.1M | 17.59 |
|
|
| Eliem Therapeutics SH (ELYM) | 0.5 | $36M | 13M | 2.74 |
|
|
| Acrivon Therapeutics SH (ACRV) | 0.4 | $34M | 4.8M | 7.15 |
|
|
| Taysha Gene Therapies SH (TSHA) | 0.4 | $31M | -41% | 11M | 2.87 |
|
| Boundless Bio SH | 0.4 | $31M | NEW | 2.2M | 14.25 |
|
| Macrogenics SH (MGNX) | 0.4 | $31M | -48% | 2.1M | 14.72 |
|
| Tenaya Therapeutics SH (TNYA) | 0.4 | $30M | +4% | 5.8M | 5.23 |
|
| Cybin SH (CYBN) | 0.3 | $24M | NEW | 58M | 0.41 |
|
| Alto Neuroscience SH | 0.3 | $21M | NEW | 1.4M | 15.35 |
|
| Cervomed SH (CRVO) | 0.3 | $20M | NEW | 862k | 23.30 |
|
| Vaxart SH (VXRT) | 0.3 | $20M | NEW | 15M | 1.30 |
|
| Bicycle Therapeutics Plc- SH (BCYC) | 0.3 | $20M | 800k | 24.90 |
|
|
| Eyepoint Pharmaceuticals SH (EYPT) | 0.2 | $19M | NEW | 939k | 20.67 |
|
| Third Harmonic Bio SH (THRD) | 0.2 | $19M | 2.0M | 9.44 |
|
|
| Pliant Therapeutics SH (PLRX) | 0.2 | $19M | 1.3M | 14.90 |
|
|
| Sera Prognostics Inc-a SH (SERA) | 0.2 | $18M | NEW | 2.0M | 9.10 |
|
| Metagenomi SH | 0.2 | $18M | NEW | 1.7M | 10.55 |
|
| Immatics Nv SH (IMTX) | 0.2 | $18M | NEW | 1.8M | 10.51 |
|
| An2 Therapeutics SH (ANTX) | 0.2 | $18M | 5.6M | 3.25 |
|
|
| Regulus Therapeutics SH (RGLS) | 0.2 | $18M | NEW | 6.3M | 2.88 |
|
| Black Diamond Therapeutics I SH (BDTX) | 0.2 | $18M | 3.5M | 5.07 |
|
|
| Adicet Bio SH (ACET) | 0.2 | $18M | NEW | 7.5M | 2.35 |
|
| Arvinas SH (ARVN) | 0.2 | $17M | 421k | 41.28 |
|
|
| Lexeo Therapeutics SH (LXEO) | 0.1 | $10M | NEW | 661k | 15.68 |
|
| Chimerix SH (CMRX) | 0.1 | $9.3M | 8.8M | 1.06 |
|
|
| Igm Biosciences SH (IGMS) | 0.1 | $9.0M | 938k | 9.65 |
|
|
| Compass Pathways SH (CMPS) | 0.1 | $6.6M | -38% | 791k | 8.32 |
|
| Curevac Nv SH (CVAC) | 0.1 | $6.0M | -28% | 2.0M | 3.03 |
|
| Unicycive Therapeutics SH (UNCY) | 0.1 | $4.8M | 3.5M | 1.38 |
|
|
| Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.0 | $3.7M | 333k | 11.04 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2024 Q1 amended filed May 17, 2024
- Ra Capital Management 2024 Q1 filed May 15, 2024
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022
- Ra Capital Management 2022 Q1 filed May 16, 2022
- Ra Capital Management 2021 Q4 filed Feb. 14, 2022
- Ra Capital Management 2021 Q3 filed Nov. 15, 2021
- Ra Capital Management 2021 Q2 filed Aug. 16, 2021
- Ra Capital Management 2021 Q1 filed May 17, 2021
- Ra Capital Management 2020 Q4 filed Feb. 16, 2021